Breaking News Instant updates and real-time market news.

ONTX

Onconova

$4.25

-0.19 (-4.28%)

07:33
03/25/19
03/25
07:33
03/25/19
07:33

Onconova surpasses 75% enrollment in Phase 3 INSPIRE study

Onconova announced that it has surpassed the 75% enrollment milestone in its pivotal Phase 3 trial of rigosertib for the potential treatment of high-risk myelodysplastic syndromes, a study known as INSPIRE.

  • 26

    Mar

ONTX Onconova
$4.25

-0.19 (-4.28%)

05/02/18
MAXM
05/02/18
UPGRADE
MAXM
Buy
Onconova upgraded to Buy from Hold at Maxim
05/03/18
MAXM
05/03/18
UPGRADE
Target $3
MAXM
Buy
Onconova upgraded to Buy at Maxim on renewed Rigosertib investor focus
As reported earlier, Maxim analyst Jason McCarthy upgraded Onconova to Buy from Hold with a price target of $3. The analyst notes that investors' focus is shifting to Rigosertib now that the company's "financing roadblock has been cleared". McCarthy believes that "Rigosertib could emerge as the first targeted therapy approved for MDS based on the mechanism of action and both prior and emerging data".
10/11/18
MAXM
10/11/18
NO CHANGE
Target $16
MAXM
Buy
Onconova price target lowered to $16 at Maxim to reflect reverse stock split
Maxim analyst Jason MacCarthy lowered his price target on Onconova to $16 from $45 to reflect the impact of the company's 1-for-15 reverse stock split announced on September 25th which reduced the number of shares outstanding to 5.67M from 85.11M. McCarthy also keeps his Buy rating on the shares and notes that his bullish stance remains intact as the company's "rigosertib phase 3 program continues to enroll and timelines remain unchanged".
12/03/18
12/03/18
NO CHANGE

Onconova presents rigosertib with azacitidine data at ASH
Onconova Therapeutics announced the presentation of the efficacy and safety results of oral rigosertib in combination with azacitidine in patients with HR-MDS reported at an oral presentation during the American Society of Hematology, or ASH. Rigosertib, the company's lead compound, is being evaluated in both intravenous and oral forms. Seventy-four patients were treated with a median age of 69 years at nine clinical sites and received either 840 mg or 1,120 mg of oral rigosertib daily divided into two doses, in combination with a standard dose of injectable azacitidine. Of the 55 evaluable patients, 29 patients were treated with a daily dose of 1,120 mg of oral rigosertib, either 560 mg twice daily or 840 mg in the a.m. and 280 mg in the afternoon. Twenty-six patients were treated with 560 mg in the AM and 280 mg in the PM for the first three weeks of a four-week cycle. All patients also received 75 mg/m2/day SC or IV azacitidine during the second week of the four-week cycle. The median duration of treatment for the HMA naive and HMA failed patients was 7.8 and 4.9 months respectively. The median duration of response in these groups was 12.2 and 10.8 months, respectively. The overall response rate, or ORR, using the IWG 2006 criteria, in 29 HMA naive patients was 90%, including 10 patients with complete remission, or CR. Among the 26 evaluable HMA-failed patients the ORR was 54% including 8% CR or PR. The median time to initial and best response were 1 and 4 cycles in the HMA naive group and 2 and 5 cycles in the HMA failed group. The safety population received at least 1 dose of oral rigosertib. The combination was well tolerated. Other than genitourinary adverse events, or AEs, the AE profile was similar to those described for azacitidine alone in this patient population. Genitourinary AEs, including hematuria and dysuria were observed. A safety optimization strategy was implemented for the higher dose cohort of 1,120 mg of oral rigosertib. These strategies included earlier in the day administration of the PM dose, oral hydration, monitoring of urinary pH and mandatory bladder emptying at night. Collectively these strategies resulted in mitigation of the target genitourinary AEs, including reduction of genitourinary grade 3 AEs reported from an earlier cohort despite receiving a higher dose of oral rigosertib. In conclusion, oral rigosertib in combination with azacitidine was well tolerated in HMA naive and HMA failed HR-MDS patients. The combination produced an encouraging rate of overall response and complete remission in both groups. The safety optimization strategies and increased dose exploration of oral rigosertib in the combination is leading to the development of a pivotal Phase 3 trial in HMA and chemotherapy naive patients. Onconova plans to meet with the FDA to discuss the results of the Phase 2 trial and the planned Phase 3 trial, and to seek a special protocol assessment. The company has partnered rigosertib with SymBio Pharmaceuticals, for Japan and Korea, and with Pint Pharma for Latin American countries. Both partners have indicated their interest in participating in the proposed new pivotal Phase 3 trial by enrolling patients in their respective territories. SymBio is currently conducting Phase 1 studies with oral rigosertib in Japan and also participating in the Phase 3 global INSPIRE trial. The company is also actively seeking additional collaborations for rigosertib in other geographies.

TODAY'S FREE FLY STORIES

SMTC

Semtech

$47.36

0.48 (1.02%)

18:38
12/11/19
12/11
18:38
12/11/19
18:38
Hot Stocks
Semtech director sells 19.3K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

CS

Credit Suisse

$12.95

-0.115 (-0.88%)

18:29
12/11/19
12/11
18:29
12/11/19
18:29
Periodicals
Former Credit Suisse JV exec claims she was put under surveillance, WSJ says »

Colleen Graham, a former…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

PANW

Palo Alto Networks

$226.76

1.71 (0.76%)

18:22
12/11/19
12/11
18:22
12/11/19
18:22
Hot Stocks
Palo Alto Networks CEO: No systematic problem with our sales »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jan

PBYI

Puma Biotechnology

$8.71

0.24 (2.83%)

18:08
12/11/19
12/11
18:08
12/11/19
18:08
Hot Stocks
Puma Biotechnology presents Phase II results of neratinib in breast cancer »

Puma Biotechnology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GTHX

G1 Therapeutics

$23.06

-0.18 (-0.77%)

18:05
12/11/19
12/11
18:05
12/11/19
18:05
Hot Stocks
G1 Therapeutics presents data from Phase 1b/2a trial of lerociclib at SABCS »

G1 Therapeutics reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NH

NantHealth

$0.86

-0.0225 (-2.54%)

18:01
12/11/19
12/11
18:01
12/11/19
18:01
Hot Stocks
NantHealth presents new breast cancer research findings at SABCS »

NantHealth announced new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWTR

Twitter

$30.56

0.71 (2.38%)

, AAPL

Apple

$270.71

2.09 (0.78%)

17:51
12/11/19
12/11
17:51
12/11/19
17:51
Hot Stocks
Twitter announces support for iOS Live Photos that will show as GIFs »

Earlier today Twitter…

TWTR

Twitter

$30.56

0.71 (2.38%)

AAPL

Apple

$270.71

2.09 (0.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

GVA

Granite Construction

$26.29

0.97 (3.83%)

17:46
12/11/19
12/11
17:46
12/11/19
17:46
Hot Stocks
Granite Construction awarded $14M site development project in Illinois »

Granite's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNRL

Brigham Minerals

$18.60

0.4 (2.20%)

17:45
12/11/19
12/11
17:45
12/11/19
17:45
Syndicate
Brigham Minerals 11M share Secondary priced at $18.10 »

Credit Suisse, Goldman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

KHC

Kraft Heinz

$31.59

-0.29 (-0.91%)

17:39
12/11/19
12/11
17:39
12/11/19
17:39
Initiation
Kraft Heinz initiated  »

Kraft Heinz resumed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

K

Kellogg

$66.17

-0.48 (-0.72%)

17:37
12/11/19
12/11
17:37
12/11/19
17:37
Initiation
Kellogg initiated  »

Kellogg resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCAU

Fiat Chrysler

$14.32

-0.085 (-0.59%)

17:34
12/11/19
12/11
17:34
12/11/19
17:34
Hot Stocks
UAW ratifies CBA with Fiat Chrysler »

UAW Fiat Chrysler U.S.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

FLO

Flowers Foods

$21.54

-0.04 (-0.19%)

17:27
12/11/19
12/11
17:27
12/11/19
17:27
Initiation
Flowers Foods initiated  »

Flowers Foods resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

17:25
12/11/19
12/11
17:25
12/11/19
17:25
General news
U.S. Treasury posted a -$208.8 B budget deficit in November »

U.S. Treasury posted a…

NOMD

Nomad Foods

$20.54

-0.12 (-0.58%)

17:23
12/11/19
12/11
17:23
12/11/19
17:23
Initiation
Nomad Foods initiated  »

Nomad Foods resumed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMPX

LMP Automotive

$15.05

1.75 (13.16%)

17:23
12/11/19
12/11
17:23
12/11/19
17:23
Hot Stocks
LMP Automotive Chairman Samer Tawfik buys over $1.7M in company shares »

LMP Automotive Chairman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGI

Triumph Group

$28.91

0.1 (0.35%)

17:21
12/11/19
12/11
17:21
12/11/19
17:21
Syndicate
Breaking Syndicate news story on Triumph Group »

Triumph Group files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MKC

McCormick

$170.70

-0.635 (-0.37%)

17:12
12/11/19
12/11
17:12
12/11/19
17:12
Initiation
McCormick initiated  »

McCormick resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLR

Continental Resources

$33.37

0.27 (0.82%)

17:10
12/11/19
12/11
17:10
12/11/19
17:10
Conference/Events
Continental Resources to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIS

General Mills

$51.57

-1.67 (-3.14%)

, K

Kellogg

$66.17

-0.48 (-0.72%)

17:08
12/11/19
12/11
17:08
12/11/19
17:08
Initiation
General Mills, Kellogg initiated  »

General Mills resumed…

GIS

General Mills

$51.57

-1.67 (-3.14%)

K

Kellogg

$66.17

-0.48 (-0.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

CEI

Camber Energy

$2.05

0.86 (72.27%)

17:05
12/11/19
12/11
17:05
12/11/19
17:05
Hot Stocks
Camber Energy responds to unusual market activity »

Camber Energy commented…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGEN

Miragen Therapeutics

$0.69

0.0554 (8.73%)

17:04
12/11/19
12/11
17:04
12/11/19
17:04
Conference/Events
Miragen Therapeutics to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGI

Alamos Gold

$5.57

0.205 (3.82%)

17:03
12/11/19
12/11
17:03
12/11/19
17:03
Hot Stocks
Alamos Gold sees FY20 production 425K-465K ounces of gold »

Alamos Gold provided 2020…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MMNFF

MedMen

$0.00

(0.00%)

17:02
12/11/19
12/11
17:02
12/11/19
17:02
Earnings
MedMen sees positive adjusted EBITDA in Q121, and positive FCF in Q321 »

The company anticipates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

CPB

Campbell Soup

$48.00

-0.37 (-0.76%)

17:02
12/11/19
12/11
17:02
12/11/19
17:02
Initiation
Campbell Soup initiated  »

Campbell Soup resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.